31654225|t|Dexmedetomidine Protects Against Oxygen-Glucose Deprivation-Induced Injury Through Inducing Astrocytes Autophagy via TSC2/mTOR Pathway.
31654225|a|Although there is an increment in stroke burden in the world, stroke therapeutic strategies are still extremely limited to a minority of patients. We previously demonstrated that dexmedetomidine (DEX) protects against focal cerebral ischemia via inhibiting neurons autophagy. Nevertheless, the role of DEX in regulating astrocytes autophagic status in oxygen-glucose deprivation, a condition that mimics cerebral ischemia, is still unknown. In this study, we have shown that DEX and DEX + RAPA (autophagy inducer) increased viability and reduced apoptosis of primary astrocytes in oxygen-glucose deprivation (OGD) model compared with DEX + 3-methyladenine (3-MA) (autophagy inhibitor). DEX induced the expression of microtubule-associated protein 1 light chain 3 (LC3) and Beclin 1, while reduced the expression of p62 in primary cultured astrocytes through induction of autophagy. In addition, DEX enhanced the expression of tuberous sclerosis complex 2 (TSC2) in primary cultured astrocytes, while reduced the expression of mammalian target of rapamycin (mTOR). In conclusion, our study suggests that DEX exerts a neuroprotection against OGD-induced astrocytes injury via activation of astrocytes autophagy by regulating the TSC2/mTOR signaling pathway, which provides a new insight into the mechanisms of DEX treatment for acute ischemic injury.
31654225	0	15	Dexmedetomidine	Chemical	MESH:D020927
31654225	33	47	Oxygen-Glucose	Chemical	-
31654225	117	121	TSC2	Gene	7249
31654225	122	126	mTOR	Gene	2475
31654225	170	176	stroke	Disease	MESH:D020521
31654225	198	204	stroke	Disease	MESH:D020521
31654225	273	281	patients	Species	9606
31654225	315	330	dexmedetomidine	Chemical	MESH:D020927
31654225	332	335	DEX	Chemical	MESH:D020927
31654225	360	377	cerebral ischemia	Disease	MESH:D002545
31654225	438	441	DEX	Chemical	MESH:D020927
31654225	488	502	oxygen-glucose	Chemical	-
31654225	540	557	cerebral ischemia	Disease	MESH:D002545
31654225	611	614	DEX	Chemical	MESH:D020927
31654225	619	622	DEX	Chemical	MESH:D020927
31654225	625	629	RAPA	Chemical	MESH:D020123
31654225	717	731	oxygen-glucose	Chemical	-
31654225	770	773	DEX	Chemical	MESH:D020927
31654225	776	791	3-methyladenine	Chemical	MESH:C025946
31654225	793	797	3-MA	Chemical	MESH:C025946
31654225	822	825	DEX	Chemical	MESH:D020927
31654225	900	903	LC3	Gene	84557
31654225	909	917	Beclin 1	Gene	8678
31654225	951	954	p62	Gene	23636
31654225	1031	1034	DEX	Chemical	MESH:D020927
31654225	1062	1090	tuberous sclerosis complex 2	Gene	7249
31654225	1092	1096	TSC2	Gene	7249
31654225	1162	1191	mammalian target of rapamycin	Gene	2475
31654225	1193	1197	mTOR	Gene	2475
31654225	1239	1242	DEX	Chemical	MESH:D020927
31654225	1288	1305	astrocytes injury	Disease	MESH:D001254
31654225	1363	1367	TSC2	Gene	7249
31654225	1368	1372	mTOR	Gene	2475
31654225	1444	1447	DEX	Chemical	MESH:D020927
31654225	1468	1483	ischemic injury	Disease	MESH:D017202
31654225	Negative_Correlation	MESH:D020927	MESH:D017202
31654225	Positive_Correlation	MESH:D020927	7249
31654225	Association	MESH:D001254	7249
31654225	Cotreatment	MESH:D020123	MESH:D020927
31654225	Positive_Correlation	MESH:D020927	84557
31654225	Negative_Correlation	MESH:D020927	2475
31654225	Negative_Correlation	MESH:D020927	MESH:D002545
31654225	Negative_Correlation	MESH:D020927	23636
31654225	Positive_Correlation	MESH:D020927	8678
31654225	Negative_Correlation	MESH:D020927	MESH:D001254

